ClinicalTrials.gg

Program

rinvecalinase alfa

Also written as “DM199” and “Recombinant human tissue kallikrein”.

Its studies are mostly in Ischemic Stroke · Kidney Diseases · Pre-Eclampsia · Renal Insufficiency, Chronic · Stroke, led by DiaMedica Therapeutics.

Furthest: phase 3, since Sep 3, 20217 company-led studies, 1 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
DiaMedica Therapeutics71 open or runningphase 3since Sep 3, 2021Apr 23, 2013Dec 2026phase 3 · NCT05065216

Also a collaborator on its studies: novotech-australia-pty-limited.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 23, 2013First study: phase 2 study in Diabetes Mellitus, Type 2First studyNCT01845064 · 98 enrolled · Netherlands
  2. Aug 8, 2016Phase 1 study in StrokeNCT02868996 · 36 enrolled · Australia
  3. Sep 18, 2017Phase 2 study in Ischemic StrokeNCT03290560 · 92 enrolled · Australia
  4. Jan 3, 2019Phase 1 study in Renal Insufficiency, ChronicNCT03795389 · 33 enrolled · United States
  5. Oct 8, 2019Phase 2 study in Kidney DiseasesNCT04123613 · 84 enrolled · United States
  6. Sep 3, 2021Phase 3 study in StrokeNCT05065216 · 728 planned · United States, Belgium, Canada and more
  7. Mar 4, 2025No phase study in Pre-EclampsiaNCT06875141

Ahead

  1. Dec 2026Primary completion: phase 3 study in StrokeNCT05065216

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06875141Pre-Eclampsia–WithdrawnMay 20250
NCT05065216Stroke · United States, Belgium, Canada and more3RecruitingDec 2026728
NCT04123613Kidney Diseases · United States2CompletedMar 16, 202284
NCT03795389Renal Insufficiency, Chronic · United States1CompletedJul 21, 201933
NCT03290560Ischemic Stroke · Australia2CompletedJan 23, 202092
NCT02868996Stroke · Australia1CompletedMar 201736
NCT01845064Diabetes Mellitus, Type 2 · Netherlands2CompletedSep 201498

How it is read

Names in the registry

  • “DM199”, 4 entries
  • “Recombinant human tissue kallikrein”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.